Blackstone Inc
ARTV

Blackstone Inc’s Artiva Biotherapeutics ARTV Stock Holding History

Blackstone Inc’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3M Buy
+2,403,437
New +$21.9M 0.07% 70

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

Blackstone Inc's ARTV Position: Q2 2026 in Review

Blackstone Inc opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 2,403,437 shares worth $23.3M. The stake represents 0.07% of the portfolio and ranks #70 among its holdings.

65 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Blackstone Inc held 2,403,437 shares of Artiva Biotherapeutics worth $23.3M as of Q2 2026.
  • Artiva Biotherapeutics was a new Blackstone Inc position in Q2 2026.
  • Artiva Biotherapeutics made up 0.07% of Blackstone Inc's portfolio in Q2 2026, its #70 holding.
  • 65 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.